elucidating hrrm status in patients with mcrpc in the propel trial
Published 1 year ago • 90 plays • Length 3:47Download video MP4
Download video MP3
Similar videos
-
1:45
the propel clinical trial exploring olaparib plus abiraterone in mcrpc
-
0:44
propel: gene-by-gene efficacy of olaparib and abiraterone in mcrpc
-
0:51
propel: analysis of drug interactions between olaparib abiraterone as 1l therapy in mcrpc
-
1:27
hrqol and pain outcomes in mcrpc: abi ala vs abi pbo in propel
-
3:07
propel: olaparib plus abiraterone as 1l treatment for metastatic crpc
-
21:21
role of immunotherapy and parp inhibitors
-
14:05
lutetium 177 psma - problems with the vision trial
-
30:48
hormone therapy & advanced therapies for prostate cancer, celestia higano, md | 2021 mid-year update
-
7:44
vision trial supports lupsma-targeting therapy for mcrpc | michael morris
-
6:41
esmo expert report on combination therapy in advanced prostate cancer @ asco gu 2022
-
43:02
part 4 – urinary tract infections (utis) with pharmacist zoom heaton
-
5:36
propel trial
-
2:59
niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer
-
0:54
convincing long-term survival with abiraterone in mcrpc
-
1:15
brcaaway: abiraterone with olaparib in mcrpc with hrr mutations
-
9:23
drs. armstrong, wallis on ai biomarkers and hrqol for localized prostate cancer, mcrpc
-
1:19
talapro-2: exploratory analyses of hrr gene subgroups in mcrpc
-
9:20
the importance of molecular testing for hrr gene mutations in patients with mcrpc
-
1:15
updates in the treatment of castration-resistant prostate cancer
-
3:33
prophecy trial: ar-v7 ctcs as a biomarker in mcrpc
-
0:33
circulating tumor cells in management of patients with castration-resistant prostate cancer
-
1:30
bmi and clinical outcomes in patients with metastatic castration-resistant prostate cancer